Answers are grounded in this paper and cite their sources.
This review synthesizes neuroimaging subtyping research in MDD, highlighting implications for precision psychiatry.
Major depressive disorder (MDD) is a highly heterogeneous condition that limits the reliability of symptom-based diagnosis and treatment selection. In response, neuroimaging-based subtyping has emerged as a promising strategy to address this heterogeneity and advance precision psychiatry. Here, we provide a critical synthesis of neuroimaging-based subtyping research in MDD with four central contributions. First, we integrate recent methodological advances-including unsupervised and semi-supervised clustering, deep learning, and normative modeling-that move the field beyond group-level averages toward individualized deviation profiles. Second, we compare convergent and divergent subtype patterns across functional, structural, diffusion, and multimodal imaging, highlighting both shared organizational principles and modality-specific dimensions of heterogeneity. Third, we evaluate emerging evidence linking neurophysiological subtypes to symptom dimensions, illness trajectories, and treatment responses and outline a translational framework for clinical implementation. Finally, we identify key challenges and actionable future directions, including the creation of large-scale harmonized datasets, rigorous validation, and integration with physiological, genetic, and environmental data. Together, this review clarifies the current state of the neuroimaging-based subtyping of MDD and delineates a roadmap for translating brain-based heterogeneity into clinically meaningful advances.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: